Education
About Us
Working with TipRanks
Follow Us
ESSA Pharma Inc. (EPIX)
:EPIX
Top Page
ESSA Pharma
(EPIX)
Select Model
Select Model
Rating:46Neutral
Price Target:―
ESSA Pharma's overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.
ESSA Pharma (EPIX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)N/A
Revenue GrowthN/A
EPS Growth9.03%
CountryUS
EmployeesN/A
SectorN/A
Sector StrengthN/A
IndustryN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ESSA Pharma Business Overview & Revenue Model
Company DescriptionESSA Pharma Inc. (EPIX) is a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer. The company operates within the biotechnology and pharmaceutical sectors, with its core products centering around small molecule drugs that target the androgen receptor pathway in prostate cancer cells. ESSA Pharma's lead product candidate is EPI-7386, a next-generation androgen receptor inhibitor designed to provide therapeutic benefits for patients with metastatic castration-resistant prostate cancer (mCRPC).
How the Company Makes MoneyESSA Pharma generates revenue primarily through partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships often involve milestone payments and royalties based on the successful development and commercialization of its product candidates. Additionally, the company may secure funding through research grants and equity financing to support its clinical trials and drug development processes. While ESSA Pharma is in the clinical-stage and does not yet have commercialized products, its potential for revenue generation lies in the successful progression and eventual approval of its drug candidates, leading to licensing deals or acquisition opportunities.
ESSA Pharma Financial Statement Overview
Summary
Income Statement
10
Very Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
ESSA Pharma Technical Analysis
Negative
―
Price Trends
0.23
Negative
0.22
Negative
0.22
Negative
Market Momentum
>-0.01
Negative
46.28
Neutral
27.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EPIX, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 0.20, equal to the 50-day MA of 0.23, and equal to the 200-day MA of 0.22, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.28 is Neutral, neither overbought nor oversold. The STOCH value of 27.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EPIX.
ESSA Pharma Peers Comparison
UnderperformOutperform
Sector (―)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― |
* Sector Average
Performance Comparison
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.